弥漫性大B细胞淋巴瘤治疗进展(4)
[19] Wilson WH，Young RM，Schmitz R，et al.Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma [J].Nat Med，2015，21(8)：922-926.
[20] 潘奕彤，吴剑秋，汤唯艳，等.复发/难治性弥漫性大B细胞淋巴瘤靶向药物及免疫治疗研究进展[J].中南药学，2018，16(3)：376-381.
[21] Pera B，Krumsiek J，Assouline SE，et al.Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway[J].Ebiomedicine，2018，28：80-89.
[22] Barnes JA，Redd R，Fisher DC，et al.Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma：Results of a phase II study[J].Hematol Oncol，2018，36(4)：633-637.
[23] Ferreri AJ，Sassone M，Zaja F，et al.Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation：An open label，single-arm，multicentre phase 2 trial[J].Lancet Haematol，2017，4(3)：e137-e146.
[24] Nowakowski GS，LaPlant B，Macon WR，et al.Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma：A phase II study[J].J Clin Oncol，2015，33(3)：251-257.
[25] Ruan NJ，Martin P，Furman RR，et al.Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphomaand mantle cell lymphoma[J].JClin Oncol，2011，29(6)：690-697.
[26] Zinzani PL，Pellegrini C，Merla E，et al.Bortezomibas salvaget reatment for heavily pretreated relapsed lymphoma patients：amulticenter retrospective study[J].Hematol Oncol，2013，31(4)：179-182.
(收稿日期：2019-04-13 修回日期：2019-04-29)
(編辑：潘明志), http://www.100md.com(刘莎 陶丽菊)
[20] 潘奕彤，吴剑秋，汤唯艳，等.复发/难治性弥漫性大B细胞淋巴瘤靶向药物及免疫治疗研究进展[J].中南药学，2018，16(3)：376-381.
[21] Pera B，Krumsiek J，Assouline SE，et al.Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway[J].Ebiomedicine，2018，28：80-89.
[22] Barnes JA，Redd R，Fisher DC，et al.Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma：Results of a phase II study[J].Hematol Oncol，2018，36(4)：633-637.
[23] Ferreri AJ，Sassone M，Zaja F，et al.Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation：An open label，single-arm，multicentre phase 2 trial[J].Lancet Haematol，2017，4(3)：e137-e146.
[24] Nowakowski GS，LaPlant B，Macon WR，et al.Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma：A phase II study[J].J Clin Oncol，2015，33(3)：251-257.
[25] Ruan NJ，Martin P，Furman RR，et al.Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphomaand mantle cell lymphoma[J].JClin Oncol，2011，29(6)：690-697.
[26] Zinzani PL，Pellegrini C，Merla E，et al.Bortezomibas salvaget reatment for heavily pretreated relapsed lymphoma patients：amulticenter retrospective study[J].Hematol Oncol，2013，31(4)：179-182.
(收稿日期：2019-04-13 修回日期：2019-04-29)
(編辑：潘明志), http://www.100md.com(刘莎 陶丽菊)